SCYNEXIS Inc (SCYX)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
$5.30-0.93%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
QuarterlyIQ Insights · SCYX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||
| Revenues | — | 20.6 | 3.7 | 140.1 | 5.1 | 13.2 | 0.0 | 0.1 | 0.3 | 0.3 | 0.3 | 0.3 | 1.3 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 0.3 | 0.3 | 0.3 | 1.3 |
| Cost of Revenues | — | — | — | — | — | — | — | — | — | — | — | — | 15.4 |
| Operating Expenses & Income | |||||||||||||
| Selling, General & Admin | 15.6 | 14.4 | 14.5 | 20.9 | 63.0 | 49.9 | 14.6 | 10.6 | 8.7 | 8.3 | 8.0 | 12.2 | 7.6 |
| R&D Expenses | 26.2 | 22.3 | 26.4 | 30.9 | 27.3 | 23.8 | 36.5 | 38.4 | 21.6 | 18.3 | 20.1 | 16.4 | 8.3 |
| Operating Income | (22.6) | (16.1) | (37.1) | 72.7 | (85.8) | (60.8) | (51.1) | (48.9) | (30.0) | (26.3) | (27.8) | (28.3) | (14.6) |
| Earnings from Continuing Operations | |||||||||||||
| Interest Expense | — | 0.2 | 0.8 | 3.1 | 5.2 | 2.7 | 1.2 | 1.0 | 1.6 | 1.5 | 0.4 | — | — |
| Other Non-Operating Income / Expenses | 12.4 | 7.5 | 16.0 | (5.5) | 18.2 | 24.9 | (7.2) | (4.8) | 10.8 | 1.3 | (2.2) | 0.0 | 7.9 |
| Asset Writedown | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.1 |
| EBT, Incl. Unusual Items | — | (8.6) | (21.1) | 67.2 | (67.5) | (36.0) | (58.3) | (53.7) | (19.2) | (25.1) | (30.0) | (28.3) | — |
| Income Tax Expense | — | — | 0.2 | 0.1 | (4.7) | (3.1) | (3.1) | 0.0 | (6.7) | 0.0 | 0.0 | 0.0 | (1.2) |
| Net Income | |||||||||||||
| Net Income | (10.2) | (8.6) | (21.3) | 67.0 | (62.8) | (32.9) | (55.2) | (53.7) | (12.5) | (25.1) | (30.0) | (32.6) | (4.2) |
| Per Share | |||||||||||||
| Basic EPS | (0.87) | (0.17) | (0.44) | 1.40 | (1.47) | (1.25) | — | — | — | — | (1.58) | (2.68) | (1.04) |
| Diluted EPS | (0.87) | (0.17) | (0.44) | 1.39 | (1.47) | (1.25) | — | — | — | — | (1.58) | (2.68) | (2.69) |
| Basic Weighted Avg Shares | 11.8 | 49.9 | 48.5 | 47.9 | 42.6 | 26.4 | — | — | — | — | 19.0 | 12.2 | 5.7 |
| Diluted Weighted Avg Shares | 11.8 | 49.9 | 48.5 | 48.4 | 42.6 | 26.4 | — | — | — | — | 19.0 | 12.2 | 5.9 |
| Supplemental | |||||||||||||
| EBITDA | — | — | — | 73.2 | (85.2) | (60.5) | (51.0) | — | — | — | — | — | — |
| EBIT | (22.6) | (16.1) | (37.1) | 72.7 | (85.8) | (60.8) | (51.1) | (48.9) | (30.0) | (26.3) | (27.8) | (28.3) | (14.6) |
| Effective Tax Rate | — | — | — | 0.2% | 7.0% | 8.6% | 5.4% | 0.0% | 35.1% | 0.0% | 0.0% | 0.0% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.